influenza modRNA vaccine

Influenza modRNA vaccines are a class of messenger RNA-based prophylactic vaccines that utilize nucleoside-modified RNA (modRNA) technology to prevent influenza infection. These vaccines consist of synthetic mRNA sequences encapsulated within lipid nanoparticles (LNPs). Upon intramuscular administration, the LNPs facilitate the entry of the modRNA into host cells, where the cellular machinery translates the genetic code into viral antigens, most commonly the hemagglutinin (HA) protein of various influenza strains. This endogenous production of antigens mimics a natural infection, triggering a comprehensive immune response that includes the generation of neutralizing antibodies and the activation of T-cells. The modRNA platform, pioneered by companies such as Pfizer, BioNTech, and Moderna, offers significant advantages over traditional egg-based manufacturing, including faster production timelines and the potential for improved strain matching. Several candidates, including Pfizer's PF-07252220 and Moderna's mRNA-1010, have advanced into Phase 3 clinical trials, both as standalone vaccines and as part of combination respiratory virus boosters.

Other names

modRNA influenza vaccinemRNA influenza vaccinemodified RNA influenza vaccine